Investigational Drug Information for Neramexane
✉ Email this page to a colleague
What is the development status for investigational drug Neramexane?
Neramexane is an investigational drug.
There have been 16 clinical trials for Neramexane.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2003.
The most common disease conditions in clinical trials are Tinnitus, Nystagmus, Pathologic, and Nystagmus, Congenital. The leading clinical trial sponsors are Merz Pharmaceuticals GmbH, Forest Laboratories, and [disabled in preview].
Summary for Neramexane
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 984 |
| WIPO Patent Applications | 553 |
| Japanese Patent Applications | 318 |
| Clinical Trial Progress | Phase 3 (2003-03-01) |
| Vendors | 29 |
Recent Clinical Trials for Neramexane
| Title | Sponsor | Phase |
|---|---|---|
| A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects | Merz Pharmaceuticals GmbH | Phase 1 |
| Changes in the Renal Excretion of Neramexane by Acidification of Urinary pH Study With and Without Application of a Urinary pH Acidification Regimen | Merz Pharmaceuticals GmbH | Phase 1 |
| Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus | Merz Pharmaceuticals GmbH | Phase 3 |
Clinical Trial Summary for Neramexane
Top disease conditions for Neramexane
Top clinical trial sponsors for Neramexane
US Patents for Neramexane
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
